General Name ：Recombinant Human Interferon α1b Injection

      Clinical Application ：Treatment of viral infections and some malignant tumors. Common applications such as:

      Infectious Disease / Liver Diseases: Chronic hepatitis B and chronic hepatitis c, epidemic hemorrhagic fever

      Pediatrics: Viral pneumonia, bronchiolitis, hand, foot and mouth disease, viral enteritis, chronic hepatitis B, chronic hepatitis C, Infectious mononucleosis, upper respiratory tract infection, viral encephalitis. Chicken pox and measles

      Oncology: Hairy cell leukemia, chronic myeloid leukemia, Melanoma, lymphoma

      Skin: condyloma acuminate, skin herpes simplex, herpes zoster

      Gynaecology: Chronic cervicitis, cervical erosion

      Other: Viral myocarditis

 

Product features:

1. Exclusive liquid injection  – Independent intellectual property rights of aqueous solutions  for 20 years

2. Good Safety – Originates from health Chinese people with mild adverse reaction and low  nAb rate.  The only interferon product approved by CFDA for pediatric clinical trials, clinical approval No.2005L3205

3. High antiviral efficacy  –  Higher expression of  STAT1 signaling  than other subtypes

4. Strong immunomodulation –  Increasing MHC II expression of mononuclear cells  and  phagocytosis function

5. High quality –  Higher purity and  less  endotoxin comparing with national standard

Awards & Recognition:

National key new product, Beijing independent innovation product, Beijing Major high-tech achievement transformation project, Zhongguancun national independent innovation demonstration area of new technologies, new products (services)